Digital Pathology: Technologies and Global Markets

Report Highlights

The global digital pathology market is expected to grow from $7.8 billion in 2024 and is projected to reach $13.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.9% during the forecast period of 2024 to 2029.

Report Includes

• 91 data tables and 57 additional tables
• An analysis of the global market for digital pathology technologies
• Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Descriptions of the upcoming market opportunities for the digital pathology market, factors driving its growth, and forecasts for this market’s segments and sub-segments
• Estimates of the market size and forecasts for the digital pathology market in value (USD millions) terms, and a corresponding market share analysis by system, type, application, end user and geographic region
• In-depth information regarding major market dynamics, technology updates, new products and applications, and COVID-19’s impact on the market for digital pathology
• Coverage of the technological, economic, and business considerations of the global market for digital pathology, with analyses and market forecasts through 2029
• Information on mergers and acquisitions, agreements, collaborations and product launches in the digital pathology industry
• Analysis of relevant patents
• A discussion of the industry’s ESG challenges and practices
• Analysis of the competitive landscape for digital pathology companies, and a value share analysis based on their segmental revenues and financial performance
• Profiles of the leading global companies, including F. Hoffmann-La Roche Ltd., 3DHISTECH Ltd., Nikon Instruments Inc., Danaher Corp., and Indica Labs Inc.

Report Scope

This report analyzes the digital pathology market, providing forecasted trends and sales projections for this market through 2029. It covers key market players, product segments, supporting technologies, emerging trends, competitive intelligence, major geographies and their competitive landscapes, and it offers regional insights. The report’s in-depth analysis of market dynamics and their impact(s) forms the foundation for its qualitative assessments and market estimates.

Digital pathology is the process of converting glass slide samples into digital images to enable electronic analysis, storage and sharing. This conversion, which enhances diagnostic accuracy, collaboration and efficiency by facilitating advanced imaging, computational analysis and telepathology, has revolutionized pathology with data-driven insights and remote consultations.

While this report outlines the conventional processes of pathology laboratories, it does not include market analysis for traditional lab devices such as microscopes and slides. The connectivity and network issues discussed are specific to data and information related to pathology lab diagnoses, excluding broader hospital-based mHealth (Mobile Health) concerns. This report’s coverage of telepathology is focused on diagnostic applications, research and development (R&D), and education and training but does not address telemedicine at a broader level.

This report addresses regulatory aspects, including innovations; technological advances (patents and approvals); and the latest trends, preferences and developments in digital pathology. As part of its analysis, it segments the digital pathology market by system, type, application and end user. The market has also been segmented into the following major geographies, North America, Asia-Pacific, Europe and the Rest of the World, and there is focused coverage of countries such as the U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, Australia, South Korea and China.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.